髄膜炎菌ワクチンの世界市場レポート 2025年

髄膜炎菌ワクチン市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は9.5％で、61億8,000万米ドルに成長します。予測期間の成長は、新型株の出現、世界化の進展、ヘルスケア投資の拡大、健康への取り組み、規制状況の変化などに起因すると考えられます。予測期間における主な動向には、個別化ワクチン、デジタル接種記録、遺伝子編集技術、多価ワクチン、定額制ワクチンモデルなどがあります。

予想されるヘルスケア支出の増加は、今後の髄膜炎菌ワクチン市場の拡大を促進すると考えられます。ヘルスケアには、住宅介護施設、看護施設、精神疾患者用中間ケア施設、精神遅滞者用中間ケア施設など、さまざまな施設が含まれます。新世代のワクチンは、以前のワクチンと比較してコストが上昇しているため、新ワクチンの利点がその価格を正当化できるかどうかが議論の焦点となっています。ワクチン接種の包括的な社会的・経済的利益を評価することは、ワクチン接種の価値に関する文献において、ますます重要な研究分野となりつつあります。例えば、2022年5月、米国の専門家団体であり医師や医学生によるロビー団体である米国医師会が発表した論文によると、米国のヘルスケア支出は9.7％増の4.1兆ドルに急増し、1人当たり1万2,530米ドルに達しました。この伸び率は2019年の4.3％を大きく上回っています。その結果、ヘルスケア支出の増加が髄膜炎菌ワクチン市場の成長を促進しています。

髄膜炎菌疾患の罹患率の上昇は、今後の髄膜炎菌ワクチン市場の成長を促進すると予想されます。髄膜炎菌感染症は、髄膜炎菌（Neisseria meningitidis）によって引き起こされる重篤な細菌感染症で、髄膜炎（脳や脊髄を包む膜の炎症）や敗血症（血流感染）を引き起こす可能性があります。髄膜炎菌ワクチンは、髄膜炎菌による髄膜炎菌性疾患の予防に高い効果を発揮します。例えば、2023年9月、南オーストラリア州の公衆衛生に重点を置く政府機関であるSA Healthは、侵襲性髄膜炎菌感染症を20例報告し、そのうち17例が血清グループBに関連し、3例が血清グループWに関連していました。したがって、髄膜炎菌性疾患の発生率の上昇は、髄膜炎菌ワクチン市場の成長の主要な促進要因です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界髄膜炎菌ワクチンPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の髄膜炎菌ワクチン市場：成長率分析
• 世界の髄膜炎菌ワクチン市場の実績：規模と成長, 2019-2024
• 世界の髄膜炎菌ワクチン市場の予測：規模と成長, 2024-2029, 2034F
• 世界髄膜炎菌ワクチン総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の髄膜炎菌ワクチン市場ワクチンの種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 髄膜炎菌結合ワクチン
• 多糖類
• 被膜下ワクチン
• 世界の髄膜炎菌ワクチン市場血清型別、実績と予測, 2019-2024, 2024-2029F, 2034F
• メン・アクウィ
• 男性B/Bc
• 男子C
• 世界の髄膜炎菌ワクチン市場：年齢層別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 乳児
• 子供たち
• 青少年と若年成人
• 大人
• 世界の髄膜炎菌ワクチン市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 薬局
• コミュニティクリニック
• 公衆衛生機関
• その他のチャンネル
• 世界の髄膜炎菌ワクチン市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 調査
• 学術機関
• 世界の髄膜炎菌ワクチン市場髄膜炎菌結合ワクチンのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 4価結合ワクチン（MenACWY）
• 二価結合ワクチン
• 世界の髄膜炎菌ワクチン市場、多糖類ワクチンの種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 髄膜炎菌多糖体ワクチン（MPSV4）
• グループC多糖体ワクチン
• 世界の髄膜炎菌ワクチン市場、カプセル下ワクチンのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 髄膜炎菌Bワクチン（MenB）
• 複合カプセル下ワクチン

第7章 地域別・国別分析

• 世界の髄膜炎菌ワクチン市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の髄膜炎菌ワクチン市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 髄膜炎菌ワクチン市場：競合情勢
• 髄膜炎菌ワクチン市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi Pasteur Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Serum Institute of India Pvt. Ltd. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bio-Manguinhos
• Walvax Biotechnology Co. Ltd.
• Bavarian Nordic A/S
• Hualan Biological Engineering Inc.
• China National Pharmaceutical Group（Sinopharm）
• Bharat Biotech
• Incepta Pharmaceuticals Ltd.
• Biological E. Limited
• Chongqing Zhifei Biological Products Co. Ltd.
• Biokangtai
• Biomed Pvt Ltd.
• Biocine SCL
• Panacea Biotec Ltd.
• Grifols S.A.
• CSL Limited

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 髄膜炎菌ワクチン市場2029：新たな機会を提供する国
• 髄膜炎菌ワクチン市場2029：新たな機会を提供するセグメント
• 髄膜炎菌ワクチン市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Meningococcal vaccinations are vaccines designed to protect against meningococcal meningitis, an infection caused by the bacterium Neisseria meningitidis, which can lead to inflammation of the membranes covering the brain and spinal cord.

Meningococcal vaccines come in several types, including meningococcal conjugate, polysaccharide, and subcapsular vaccines. Meningococcal conjugate vaccines combine a polysaccharide antigen with a carrier molecule. Different serotypes are available, such as Men ACWY, Men B or BC, and Men C, targeting infants, children, adolescents, young adults, and adults. These vaccines are distributed through pharmacies, community clinics, public health agencies, and other outlets, serving end-users such as hospitals, research institutions, and academic institutes.

The meningococcal vaccines market research report is one of a series of new reports from The Business Research Company that provides meningococcal vaccines market statistics, including the meningococcal vaccines industry's global market size, regional shares, competitors with a meningococcal vaccines market share, detailed meningococcal vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the meningococcal vaccines industry. The meningococcal vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The meningococcal vaccines market size has grown rapidly in recent years. It will grow from $3.89 billion in 2024 to $4.29 billion in 2025 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to disease incidence, global travel trends, healthcare infrastructure, epidemic preparedness, health insurance coverage.

The meningococcal vaccines market size is expected to see strong growth in the next few years. It will grow to $6.18 billion in 2029 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to emergence of new strains, increasing globalization, growing healthcare investments, health initiatives, changing regulatory landscape. Major trends in the forecast period include personalized vaccines, digital vaccination records, gene editing technologies, multi-valent vaccines, subscription-based vaccine models.

The anticipated rise in healthcare expenditure is poised to drive the expansion of the meningococcal vaccine market in the future. Healthcare encompasses various facilities such as residential care institutions, nursing facilities, intermediate care facilities for individuals with mental illnesses, or intermediate care facilities for individuals with mental retardation. The increasing cost of new vaccine generations compared to their predecessors has become a focal point in debates regarding whether the benefits of these new vaccines justify their prices. Evaluating the comprehensive social and economic benefits of vaccination is becoming an increasingly vital area of study in the literature on the value of vaccination. For example, in May 2022, an article published by the American Medical Association, a US-based professional association and lobbying group of physicians and medical students, reported that healthcare spending in the United States had surged by 9.7% to $4.1 trillion, amounting to $12,530 per person. This growth rate is significantly higher than that of 2019, which was 4.3%. Consequently, the increase in healthcare spending is propelling the growth of the meningococcal vaccine market.

The rising incidence of meningococcal disease is expected to drive the growth of the meningococcal vaccine market in the future. Meningococcal disease is a severe bacterial infection caused by Neisseria meningitidis, which can lead to meningitis (inflammation of the membranes surrounding the brain and spinal cord) and septicemia (bloodstream infection). Meningococcal vaccines are highly effective in preventing meningococcal disease caused by Neisseria meningitidis. For example, in September 2023, SA Health, a government agency in South Australia focused on public health, reported 20 instances of invasive meningococcal disease, with 17 cases associated with serogroup B and three cases linked to serogroup W. This represents an increase from the 14 cases reported in 2022. Therefore, the rising incidence of meningococcal disease is a key driver of the growth of the meningococcal vaccine market.

Key players in the meningococcal vaccines market are actively engaged in the development of new vaccines targeting various serogroups, aiming to enhance their market profitability. Meningococcal vaccines serve as preventive measures, guarding individuals against infections caused by specific serogroups of the Neisseria meningitidis bacteria. Notably, in October 2023, Pfizer Inc., a renowned US-based pharmaceutical company, obtained FDA approval for its vaccine, PENBRAYA. Distinguished by its extensive serogroup coverage, PENBRAYA stands as the most comprehensive meningococcal vaccine sanctioned in the United States, providing protection against serogroups A, B, C, W, and Y. The FDA's endorsement of PENBRAYA is supported by robust Phase 2 and 3 trial data, affirming its non-inferior immunogenicity when compared to Trumenba + Menveo across all targeted serogroups, coupled with favorable safety profiles. Additionally, Pfizer's September 2022 announcement highlighted positive outcomes from a Phase 3 trial, showcasing PENBRAYA's safety, tolerability, and immunogenicity compared to existing licensed meningococcal vaccines.

Major companies in the meningococcal vaccines market are strategically engaging in partnerships to bolster their profitability within the market. These collaborations involve cooperative efforts among pharmaceutical firms, research institutions, government bodies, and non-profit organizations, aimed at collectively advancing the development, production, distribution, or enhancement of meningococcal vaccines. For instance, in July 2023, the Serum Institute of India, a biotechnology company based in India, partnered with PATH, a US-based non-profit health organization, to develop MenFive. The Serum Institute of India received WHO prequalification for MenFive, a multivalent meningococcal meningitis vaccine. MenFive stands as the first conjugate vaccine of its kind, targeting the primary causes of meningococcal meningitis prevalent in Africa. This vaccine follows the success of MenAfriVac, introduced in 2010, which successfully eradicated serogroup A meningococcal meningitis outbreaks in the African meningitis belt. MenFive is designed to prevent fatalities and disabilities caused by the disease. The Serum Institute of India's groundbreaking vaccines contribute significantly to the ongoing fight against meningococcal meningitis in Africa.

In August 2022, GlaxoSmithKline PLC, a pharmaceutical and biotechnology company headquartered in the UK, completed the acquisition of Affinivax Inc. for $3.3 billion. GSK's acquisition of Affinivax aligns with its strategic goal of building a diverse portfolio encompassing specialty medicines and vaccines. Affinivax, Inc., based in the US, specializes in next-generation vaccine technology and operates within the meningococcal vaccines sector.

Major companies operating in the meningococcal vaccines market include Pfizer Inc., GlaxoSmithKline plc, Sanofi Pasteur, Merck & Co. Inc., Serum Institute of India Pvt. Ltd., Bio-Manguinhos, Walvax Biotechnology Co. Ltd., Bavarian Nordic A/S, Hualan Biological Engineering Inc., China National Pharmaceutical Group (Sinopharm), Bharat Biotech, Incepta Pharmaceuticals Ltd., Biological E. Limited, Chongqing Zhifei Biological Products Co. Ltd., Biokangtai, Biomed Pvt Ltd., Biocine SCL, Panacea Biotec Ltd., Grifols S.A., CSL Limited, Minhai Biotechnology Co. Ltd., Chiron Behring Vaccines Pvt. Ltd., Shenzhen Kangtai Biological Products Co. Ltd.

North America was the largest region in the meningococcal vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the meningococcal vaccines market report during the forecast period. The regions covered in the meningococcal vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the meningococcal vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The meningococcal vaccines market consists of sales of conjugate vaccines, combination vaccines, serogroup B vaccine products, and other types. Values in this market are 'pharmaceuticals' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Meningococcal Vaccines Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on meningococcal vaccines market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for meningococcal vaccines ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The meningococcal vaccines market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Vaccine Type: Meningococcal Conjugate Vaccine; Polysaccharide; Subcapsular Vaccine
• 2) By Serotype: Men Acwy; Men B/Bc; Men C
• 3) By Age Group: Infants; Children; Adolescents and Young Adults; Adults
• 4) By Distribution Channel:: Pharmacies; Community Clinics; Public Health Agencies; Other Channels
• 5) By End user: Hospitals; Research; Academic Institutes
• Subsegments:
• 1) By Meningococcal Conjugate Vaccine: Quadrivalent Conjugate Vaccine (MenACWY); Bivalent Conjugate Vaccine
• 2) By Polysaccharide Vaccine: Meningococcal Polysaccharide Vaccine (MPSV4); Group C Polysaccharide Vaccine
• 3) By Subcapsular Vaccine: Meningococcal B Vaccine (MenB); Combination Subcapsular Vaccines
• Companies Mentioned: Pfizer Inc.; GlaxoSmithKline plc; Sanofi Pasteur; Merck & Co. Inc.; Serum Institute of India Pvt. Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Meningococcal Vaccines Market Characteristics

3. Meningococcal Vaccines Market Trends And Strategies

4. Meningococcal Vaccines Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Meningococcal Vaccines Growth Analysis And Strategic Analysis Framework

• 5.1. Global Meningococcal Vaccines PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Meningococcal Vaccines Market Growth Rate Analysis
• 5.4. Global Meningococcal Vaccines Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Meningococcal Vaccines Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Meningococcal Vaccines Total Addressable Market (TAM)

6. Meningococcal Vaccines Market Segmentation

• 6.1. Global Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Meningococcal Conjugate Vaccine
• Polysaccharide
• Subcapsular Vaccine
• 6.2. Global Meningococcal Vaccines Market, Segmentation By Serotype, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Men Acwy
• Men B/Bc
• Men C
• 6.3. Global Meningococcal Vaccines Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Infants
• Children
• Adolescents and Young Adults
• Adults
• 6.4. Global Meningococcal Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pharmacies
• Community Clinics
• Public Health Agencies
• Other Channels
• 6.5. Global Meningococcal Vaccines Market, Segmentation By End user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Research
• Academic Institutes
• 6.6. Global Meningococcal Vaccines Market, Sub-Segmentation Of Meningococcal Conjugate Vaccine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Quadrivalent Conjugate Vaccine (MenACWY)
• Bivalent Conjugate Vaccine
• 6.7. Global Meningococcal Vaccines Market, Sub-Segmentation Of Polysaccharide Vaccine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Meningococcal Polysaccharide Vaccine (MPSV4)
• Group C Polysaccharide Vaccine
• 6.8. Global Meningococcal Vaccines Market, Sub-Segmentation Of Subcapsular Vaccine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Meningococcal B Vaccine (MenB)
• Combination Subcapsular Vaccines

7. Meningococcal Vaccines Market Regional And Country Analysis

• 7.1. Global Meningococcal Vaccines Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Meningococcal Vaccines Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Meningococcal Vaccines Market

• 8.1. Asia-Pacific Meningococcal Vaccines Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Meningococcal Vaccines Market, Segmentation By Serotype, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Meningococcal Vaccines Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Meningococcal Vaccines Market

• 9.1. China Meningococcal Vaccines Market Overview
• 9.2. China Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Meningococcal Vaccines Market, Segmentation By Serotype, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Meningococcal Vaccines Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Meningococcal Vaccines Market

• 10.1. India Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Meningococcal Vaccines Market, Segmentation By Serotype, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Meningococcal Vaccines Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Meningococcal Vaccines Market

• 11.1. Japan Meningococcal Vaccines Market Overview
• 11.2. Japan Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Meningococcal Vaccines Market, Segmentation By Serotype, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Meningococcal Vaccines Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Meningococcal Vaccines Market

• 12.1. Australia Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Meningococcal Vaccines Market, Segmentation By Serotype, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Meningococcal Vaccines Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Meningococcal Vaccines Market

• 13.1. Indonesia Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Meningococcal Vaccines Market, Segmentation By Serotype, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Meningococcal Vaccines Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Meningococcal Vaccines Market

• 14.1. South Korea Meningococcal Vaccines Market Overview
• 14.2. South Korea Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Meningococcal Vaccines Market, Segmentation By Serotype, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Meningococcal Vaccines Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Meningococcal Vaccines Market

• 15.1. Western Europe Meningococcal Vaccines Market Overview
• 15.2. Western Europe Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Meningococcal Vaccines Market, Segmentation By Serotype, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Meningococcal Vaccines Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Meningococcal Vaccines Market

• 16.1. UK Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Meningococcal Vaccines Market, Segmentation By Serotype, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Meningococcal Vaccines Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Meningococcal Vaccines Market

• 17.1. Germany Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Meningococcal Vaccines Market, Segmentation By Serotype, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Meningococcal Vaccines Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Meningococcal Vaccines Market

• 18.1. France Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Meningococcal Vaccines Market, Segmentation By Serotype, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Meningococcal Vaccines Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Meningococcal Vaccines Market

• 19.1. Italy Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Meningococcal Vaccines Market, Segmentation By Serotype, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Meningococcal Vaccines Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Meningococcal Vaccines Market

• 20.1. Spain Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Meningococcal Vaccines Market, Segmentation By Serotype, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Meningococcal Vaccines Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Meningococcal Vaccines Market

• 21.1. Eastern Europe Meningococcal Vaccines Market Overview
• 21.2. Eastern Europe Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Meningococcal Vaccines Market, Segmentation By Serotype, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Meningococcal Vaccines Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Meningococcal Vaccines Market

• 22.1. Russia Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Meningococcal Vaccines Market, Segmentation By Serotype, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Meningococcal Vaccines Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Meningococcal Vaccines Market

• 23.1. North America Meningococcal Vaccines Market Overview
• 23.2. North America Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Meningococcal Vaccines Market, Segmentation By Serotype, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Meningococcal Vaccines Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Meningococcal Vaccines Market

• 24.1. USA Meningococcal Vaccines Market Overview
• 24.2. USA Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Meningococcal Vaccines Market, Segmentation By Serotype, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Meningococcal Vaccines Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Meningococcal Vaccines Market

• 25.1. Canada Meningococcal Vaccines Market Overview
• 25.2. Canada Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Meningococcal Vaccines Market, Segmentation By Serotype, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Meningococcal Vaccines Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Meningococcal Vaccines Market

• 26.1. South America Meningococcal Vaccines Market Overview
• 26.2. South America Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Meningococcal Vaccines Market, Segmentation By Serotype, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Meningococcal Vaccines Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Meningococcal Vaccines Market

• 27.1. Brazil Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Meningococcal Vaccines Market, Segmentation By Serotype, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Meningococcal Vaccines Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Meningococcal Vaccines Market

• 28.1. Middle East Meningococcal Vaccines Market Overview
• 28.2. Middle East Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Meningococcal Vaccines Market, Segmentation By Serotype, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Meningococcal Vaccines Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Meningococcal Vaccines Market

• 29.1. Africa Meningococcal Vaccines Market Overview
• 29.2. Africa Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Meningococcal Vaccines Market, Segmentation By Serotype, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Meningococcal Vaccines Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Meningococcal Vaccines Market Competitive Landscape And Company Profiles

• 30.1. Meningococcal Vaccines Market Competitive Landscape
• 30.2. Meningococcal Vaccines Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Sanofi Pasteur Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Serum Institute of India Pvt. Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Meningococcal Vaccines Market Other Major And Innovative Companies

• 31.1. Bio-Manguinhos
• 31.2. Walvax Biotechnology Co. Ltd.
• 31.3. Bavarian Nordic A/S
• 31.4. Hualan Biological Engineering Inc.
• 31.5. China National Pharmaceutical Group (Sinopharm)
• 31.6. Bharat Biotech
• 31.7. Incepta Pharmaceuticals Ltd.
• 31.8. Biological E. Limited
• 31.9. Chongqing Zhifei Biological Products Co. Ltd.
• 31.10. Biokangtai
• 31.11. Biomed Pvt Ltd.
• 31.12. Biocine SCL
• 31.13. Panacea Biotec Ltd.
• 31.14. Grifols S.A.
• 31.15. CSL Limited

32. Global Meningococcal Vaccines Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Meningococcal Vaccines Market

34. Recent Developments In The Meningococcal Vaccines Market

35. Meningococcal Vaccines Market High Potential Countries, Segments and Strategies

• 35.1 Meningococcal Vaccines Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Meningococcal Vaccines Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Meningococcal Vaccines Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer